Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 diabetes, high blood pressure and high cholesterol, according to the report published in the New England Journal of Medicine.
Tirzepatide 15 mg produced similar weight loss results as bariatric surgery among patients with obesity but had a favorable safety profile, according to a presenter at the ACG Annual Scientific Meeting.
A team of researchers led by Pennington Biomedical Research Center's Dr. Florina Corpodean has confirmed through a data analysis that metabolic and bariatric surgery is largely safe and effective for patients who are experiencing severe obesity.
Dubbed the One Meal a Day (OMAD) diet, it’s a form of intermittent fasting that involves eating all the day’s calories in a single meal, after 23 hours of fasting.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
